2 results
Approved WMORecruiting
Objective: To demonstrate the efficacy of a novel matrix therapy based technology that creates improved wound healing in a clinical donor site model.
Approved WMOWill not start
Primary Objective:To compare the efficacy of BMS-986142 versus placebo on a background of MTX as assessed by ACR20 and ACR70 response rates at week 12.Secondary Objectives:1) Assess additional efficacy outcomes of BMS-986142 at week 12 and over 12…